

Gram Negative Rods

% Sensitive	EAST TENNESSEE Children's Hospital											
	E coli ¹	E. cloacae Complex	Kleb pneumoniae ²	Klebsiella oxytoca ²	P mirabilis ³	P aeruginosa	S marcescens	Shigella sonneii	Salmonella species	Acinetobacter baumannii	H. influenzae ⁵	
#isolates	1608	88	138	34	73	294	64	2	32	23	155	
Amikacin	98	100	91	100	100	80	97	*	*	***	X	
Amoxicillin/Clav	85	**	95	94	99	**	**	100	100	**	84	
Ampicillin	53	**	**	**	89	**	**	100	94	**	50	
Ampicillin/Sulbact	57	**	83	68	96	**	**	100	94	100	X	
Cefazolin	94	**	92	86	97	**	**	*	*	0	X	
Ceftazidime	96	80	93	94	99	87	98	100	100	86	93	
Ceftriaxone	96	80	93	94	99	**	92	100	97	23	95	
Ciprofloxacin	89	100	98	100	97	72	98	100	100	100	100	
ESBL Negative	96	N/A	94	91	X	N/A	N/A	N/A	N/A	N/A	N/A	
Gentamicin	93	100	97	97	96	87	92	*	*	100	X	
Imipenem	100	100	100	100	***	91	X	X	100	100	X	
Levofloxacin	89	99	98	100	97	77	98	X	100	100	X	
Meropenem	100	100	96	100	100	97	100	X	100	100	100	
Nitrofurantoin ⁴	97	36	31	89	**	**	**	100	97	X	X	
Piperacillin/Tazo	97	89	97	94	100	96	***	***	***	100	X	
SMX/TRI	77	83	84	91	92	**	X	0	100	X	62	
Tobramycin	93	98	94	97	96	85	77	*	*	100	X	

X = Place holder/not tested N/A - Not applicable

* = Aminoglycosides, first and second generation cephalosporins, and cephamycins may appear active *in vitro*, but are not effective clinically, should not be reported.

** = Intrinsically resistant *** = Not reported for these organisms on Vitek

1. Includes E coli with Extended Beta Lactamase Spectrum (ESBL)
2. Includes Klebsiella with Extended Beta Lactamase Spectrum (ESBL)
3. Proteus mirabilis can be intermediate or resistant to imipenem due to other mechanisms that carbapenemases; is intrinsically resistant to Polymyxin B., Colistin, and Tetracyclines.
4. For use in Urine Only.
5. Kirby-Bauer susceptibilities

Form 31345 (8-20)



Antibiogram Report

July 1, 2019 through
June 30, 2020

Provided by:

Pharmacy & Therapeutics,
Drug Utilization Committee
and
Infection Prevention Committee

Gram Negative Rods

% Sensitive	EAST TENNESSEE Children's Hospital											
	E coli ¹	E. cloacae Complex	Kleb pneumoniae ²	Klebsiella oxytoca ²	P mirabilis ³	P aeruginosa	S marcescens	Shigella sonneii	Salmonella species	Acinetobacter baumannii	H. influenzae ⁵	
#isolates	1608	88	138	34	73	294	64	2	32	23	155	
Amikacin	98	100	91	100	100	80	97	*	*	***	X	
Amoxicillin/Clav	85	**	95	94	99	**	**	100	100	**	84	
Ampicillin	53	**	**	**	89	**	**	100	94	**	50	
Ampicillin/Sulbact	57	**	83	68	96	**	**	100	94	100	X	
Cefazolin	94	**	92	86	97	**	**	*	*	0	X	
Ceftazidime	96	80	93	94	99	87	98	100	100	86	93	
Ceftriaxone	96	80	93	94	99	**	92	100	97	23	95	
Ciprofloxacin	89	100	98	100	97	72	98	100	100	100	100	
ESBL Negative	96	N/A	94	91	X	N/A	N/A	N/A	N/A	N/A	N/A	
Gentamicin	93	100	97	97	96	87	92	*	*	100	X	
Imipenem	100	100	100	100	***	91	X	X	100	100	X	
Levofloxacin	89	99	98	100	97	77	98	X	100	100	X	
Meropenem	100	100	96	100	100	97	100	X	100	100	100	
Nitrofurantoin ⁴	97	36	31	89	**	**	**	100	97	X	X	
Piperacillin/Tazo	97	89	97	94	100	96	***	***	***	100	X	
SMX/TRI	77	83	84	91	92	**	X	0	100	X	62	
Tobramycin	93	98	94	97	96	85	77	*	*	100	X	

X = Place holder/not tested N/A - Not applicable

* = Aminoglycosides, first and second generation cephalosporins, and cephamycins may appear active *in vitro*, but are not effective clinically, should not be reported.

** = Intrinsically resistant *** = Not reported for these organisms on Vitek

1. Includes E coli with Extended Beta Lactamase Spectrum (ESBL)
2. Includes Klebsiella with Extended Beta Lactamase Spectrum (ESBL)
3. Proteus mirabilis can be intermediate or resistant to imipenem due to other mechanisms that carbapenemases; is intrinsically resistant to Polymyxin B., Colistin, and Tetracyclines.
4. For use in Urine Only.
5. Kirby-Bauer susceptibilities

Form 31345 (8-20)



Antibiogram Report

July 1, 2019 through
June 30, 2020

Provided by:

Pharmacy & Therapeutics,
Drug Utilization Committee
and
Infection Prevention Committee

Gram Positive

% Sensitive

	E. faecalis	E. faecium	MRSA	MSSA	S. epidermidis	S. pneumoniae	Strep agalactiae (Group B)
#isolates	113	2	677	539	185	74	85
Ampicillin	100	0	0	0	X	X	100
Penicillin	100	0	0	0	1	40	100
Oxacillin	**	**	0	100	45	N/A	N/A
Ciprofloxacin	96	0	49	86	84	*	N/A
Levofloxacin	98	0	51	88	85	99	100
Vancomycin	100	50	100	100	100	100	100
Clindamycin	**	**	68	75	68	73	54
Inducible clindamycin resistance absent	N/A	N/A	94	81	97	93	93
Erythromycin	10	0	15	52	32	29	20
Cefotaxime	**	**	0***	100***	45***	89	99
Ceftriaxone	**	**	0***	100***	45***	89	100
SMX-TRI	**	**	87	97	68	61	N/A
Linezolid	100	100	100	100	99	100	N/A
Quinup/Dalfo	**	**	100	100	100	N/A	N/A
Strept Synergy	84	100	N/A	N/A	N/A	N/A	N/A
Gent Synergy	88	100	N/A	N/A	N/A	N/A	N/A

* = No CLSI guidelines for susceptibilities

** = Intrinsically resistant

*** = Deduced based on Oxacillin/Cefoxitin Screen

N/A = not applicable

X = place holder; not tested on organism.

Gram Positive

% Sensitive

	E. faecalis	E. faecium	MRSA	MSSA	S. epidermidis	S. pneumoniae	Strep agalactiae (Group B)
#isolates	113	2	677	539	185	74	85
Ampicillin	100	0	0	0	X	X	100
Penicillin	100	0	0	0	1	40	100
Oxacillin	**	**	0	100	45	N/A	N/A
Ciprofloxacin	96	0	49	86	84	*	N/A
Levofloxacin	98	0	51	88	85	99	100
Vancomycin	100	50	100	100	100	100	100
Clindamycin	**	**	68	75	68	73	54
Inducible clindamycin resistance absent	N/A	N/A	94	81	97	93	93
Erythromycin	10	0	15	52	32	29	20
Cefotaxime	**	**	0***	100***	45***	89	99
Ceftriaxone	**	**	0***	100***	45***	89	100
SMX-TRI	**	**	87	97	68	61	N/A
Linezolid	100	100	100	100	99	100	N/A
Quinup/Dalfo	**	**	100	100	100	N/A	N/A
Strept Synergy	84	100	N/A	N/A	N/A	N/A	N/A
Gent Synergy	88	100	N/A	N/A	N/A	N/A	N/A

* = No CLSI guidelines for susceptibilities

** = Intrinsically resistant

*** = Deduced based on Oxacillin/Cefoxitin Screen

N/A = not applicable

X = place holder; not tested on organism.